Finasteride for the treatment and control of benign prostatic hyperplasia: Summary of phase III controlled studies

P. Grino, E. Stoner, G. L. Andriole, R. Boake, B. R. Bracken, W. Brannan, R. C. Bruskewitz, C. E. Cox, G. R. Cunningham, P. C. Devine, P. F. Schellhammer

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

The efficacy and safety profiles of finasteride were tested in 1,645 patients with benign prostatic hyperplasia (BPH) over a 12-month period. The following effects were observed: (1) a 60-80% reduction in serum dihydrotestosterone levels; (2) a 20% reduction in prostate volume; (3) significant increases in the maximum urinary flow rate compared with placebo; and (4) significant improvement in urinary symptoms, particularly obstructive symptoms. All effects were well maintained for the entire duration of the study. Finasteride had a good safety profile and was well tolerated.

Original languageEnglish
Pages (from-to)24-28
Number of pages5
JournalEuropean Urology
Volume25
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 1 1994

Keywords

  • 5α-Reductase
  • Androgens
  • Dihydrotestosterone
  • Urinary flow rate

Fingerprint

Dive into the research topics of 'Finasteride for the treatment and control of benign prostatic hyperplasia: Summary of phase III controlled studies'. Together they form a unique fingerprint.

Cite this